Impact of interleukin‐28B polymorphism on HCV‐1 infected patients treated with response‐guided therapy

ADVANCES IN DIGESTIVE MEDICINE - Tập 2 - Trang 25-32 - 2015
Tsung-Ming Chen1, Pi-Teh Huang1, Bio-Chia Show2, Chen-Fan Wen3, Yi-Ping Chen3
1Division of Hepato-Gastroenterology, Department of Internal Medicine, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan
2Division of Medical Laboratory, Department of Pathology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan
3Department of Medical Research, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan

Tóm tắt

SummaryBackgroundSingle nucleotide polymorphisms (SNPs) of interleukin‐28B (IL28B) were associated with sustained virological response (SVR) in hepatitis C virus genotype 1 (HCV‐1) infected patients treated with a standard 48‐week regimen of peginterferon and ribavirin combination. Whether IL28B SNP genotype would be the influential prognosticator for patients treated with response‐guided therapy (RGT) is still not well understood.AimsTo investigate the impact of IL28B rs809917 genotype on HCV‐1 infected patients treated with RGT.MethodsA total of 128 consecutive treatment‐naïve HCV‐1 infected patients between July 2006 and July 2011 were analyzed. For rapid virological response (RVR) patients, we allowed an abbreviated 24‐week regimen regardless of baseline viral loads; otherwise, a 48‐week regimen was implemented (for patients with early virological response). The IL28B rs8099917 SNP genotypes were determined accordingly.ResultsA total of 117 patients (91.4%) were of rs8099917 TT genotype and 11 (8.6%) were of GT/GG genotype. Eighty‐two of the 128 (64.1%) patients achieved SVR, occurring in 54 of 67 RVR patients (80.6%) and 28 of 61 non‐RVR patients (45.9%, p < 0.001). Compared to the GT/GG genotype, patients with the TT genotype had significantly higher SVR rates (67.5% vs. 27.3%; p = 0.008) and low relapse rates (28.2% vs. 70.0%; p = 0.006). The multivariate analysis showed that RVR (odds ratio, 4.51; 95% confidence interval, 1.87–10.90; p = 0.001) and rs8099917 TT genotype (odds ratio, 6.91; 95% confidence interval, 1.53–31.17; p = 0.012) were independent factors associated with SVR.ConclusionFor HCV‐1 infected patients who were treated with RGT, the IL28B unfavorable genotype predicted a higher relapse rate; RVR and IL28B favorable genotype were independent factors associated with SVR in patients treated with RGT.

Tài liệu tham khảo

10.1007/s12072-012-9342-y 10.1016/S0140-6736(01)06102-5 10.1056/NEJMoa020047 10.7326/0003-4819-140-5-200403020-00010 10.1086/523585 Zeuzem S., 2008, Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?, Antivir Ther, 13, 747, 10.1177/135965350801300614 10.1016/j.jhep.2007.07.015 10.1111/j.1365-2893.2008.01012.x 10.1002/hep.22061 10.1086/592579 10.1002/hep.22319 10.1002/hep.21159 10.1038/nature08309 10.1038/nature08463 10.1038/ng.449 10.1038/ng.447 10.1053/j.gastro.2010.04.013 10.1016/j.jhep.2011.03.029 10.1016/j.antiviral.2011.12.002 10.3851/IMP2322 10.3851/IMP2026 10.1002/hep.24546 10.1053/jhep.2003.50346 10.1111/j.1440-1746.2009.05946.x
Thông tin
Thông tin xuất bản

ADVANCES IN DIGESTIVE MEDICINE

Tập 2

25-32

Thông tin tác giả